nifedipine has been researched along with Diabetes Mellitus, Type 2 in 82 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 9.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "In this selected sample of patients with type 2 diabetes and mild hypertension, both telmisartan and nifedipine GITS produced significant reductions in blood pressure." | 9.11 | Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubl ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Piccinni, MN, 2004) |
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 9.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| "Both amlodipine and nifedipine retard are relatively safe and useful in the treatment of hypertension in Chinese Type 2 diabetic patients." | 9.09 | Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 9.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "Our study compared the effects of an angiotensin-converting enzyme inhibitor (captopril) versus a calcium antagonist (nifedipine) on proteinuria and renal function in patients with diabetic nephropathy." | 9.07 | Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. ( Audi, L; Lucas, A; Romero, R; Salinas, I; Sanmarti, A; Teixidó, J, 1992) |
| "In this case report, we describe the clinical course over a 14-year follow-up in a 47-year-old diabetes patient with severe chronic periodontitis and nifedipine-induced gingival overgrowth." | 7.78 | Clinical case report of long-term follow-up in type-2 diabetes patient with severe chronic periodontitis and nifedipine-induced gingival overgrowth. ( Fujinami, K; Shibukawa, Y; Yamashita, S, 2012) |
| "The combination with olmesartan and nifedipine, as well as a monotherapy with olmesartan, exerts preferable cardioprotection in diabetic mice exposed to recurrent hypoxia." | 7.76 | Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice. ( Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T, 2010) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 7.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 7.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 6.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "Twenty-five stage 2 diabetic nephropathy patients, 39 stage 3 diabetic nephropathy patients, and 12 nondiabetic subjects performed five submaximal cycloergometric exercises (90% of theoretical heart rate) on nonconsecutive days." | 6.67 | Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. ( Bossoni, S; Caldonazzo, A; Cimino, A; Cravarezza, P; Giustina, A; Giustina, G; Romanelli, G, 1990) |
| "The pathogenesis of vascular calcification is incompletely understood, and until now, there have been no effective therapeutics for vascular calcification." | 5.91 | L-type calcium ion channel-mediated activation of autophagy in vascular smooth muscle cells via thonningianin A (TA) alleviates vascular calcification in type 2 diabetes mellitus. ( Li, P; Liu, R; Liu, Y; Shen, J; Sun, X; Wai Wong, VK; Wang, Q; Zhang, C; Zhao, M, 2023) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 5.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| "In this selected sample of patients with type 2 diabetes and mild hypertension, both telmisartan and nifedipine GITS produced significant reductions in blood pressure." | 5.11 | Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubl ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Piccinni, MN, 2004) |
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 5.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| "Both amlodipine and nifedipine retard are relatively safe and useful in the treatment of hypertension in Chinese Type 2 diabetic patients." | 5.09 | Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001) |
| "To evaluate the effects of cilnidipine (CNP), L- and N-type calcium channel blocker and nilvadipine (NVP) on 24-h urinary epinephrine (U-EP), norepinephrine (U-NE), dopamine (U-DA) and C-peptide (U-CPR) in patients associated with hypertension and non-insulin-dependent diabetes mellitus (HT-NIDDM), a randomized crossover study was performed with 35 HT-NIDDM patients." | 5.09 | Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. ( Hattori, Y; Irie, M; Takeda, S; Ueshiba, H, 1999) |
| " In a prospective randomized study, 14 patients with NIDDM, hypertension, proteinuria, and renal insufficiency were given either isradipine (n = 7) or nifedipine XL (n = 7) for 6 months." | 5.08 | Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. ( Abbott, K; Bakris, GL; Smith, A, 1996) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| " Angiotensin converting enzyme inhibitors (ACE-I) significantly retarded the development of end-stage renal failure compared to antihypertensives other than ACE-I (mostly nifedipine), and the effect was evident particularly in patients with proteinuria below the median (2." | 5.08 | Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. ( Babazono, T; Hirayama, M; Ishii, A; Omori, Y; Takahashi, C; Takeda, M; Tomonaga, O; Ujihara, U; Yokoyama, H, 1997) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 5.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "In the patients treated with enalapril, albuminuria decreased from 143 +/- 64 (mean +/- SD) mg/24 h to 122 +/- 67 mg/24 h during the first year." | 5.07 | Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. ( Bental, T; Jutrin, I; Katz, B; Lishner, M; Ravid, M; Savin, H, 1993) |
| "To compare the effects of nifedipine and enalapril on carbohydrate and lipoprotein metabolism in Chinese non-insulin-dependent diabetes mellitus (NIDDM) patients with hypertension." | 5.07 | The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM. ( Chan, JC; Cockram, CS; Leung, DH; Nicholls, MG; Tomlinson, B; Yeung, VT, 1994) |
| "Our study compared the effects of an angiotensin-converting enzyme inhibitor (captopril) versus a calcium antagonist (nifedipine) on proteinuria and renal function in patients with diabetic nephropathy." | 5.07 | Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. ( Audi, L; Lucas, A; Romero, R; Salinas, I; Sanmarti, A; Teixidó, J, 1992) |
| "The effects of one month's treatment with each of nifedipine, verapamil, diltiazem, propranolol and placebo, given in random order, on fasting plasma glucose, haemoglobin Alc, serum fructosamine, immunoreactive insulin, cholesterol, and triglyceride were studied in a group of 19 patients with hypertension and non-insulin dependent diabetes mellitus." | 5.06 | The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. ( Chellingsworth, MC; Kendall, MJ; Pasi, J; Singh, BM; Wright, AD, 1989) |
| "In this case report, we describe the clinical course over a 14-year follow-up in a 47-year-old diabetes patient with severe chronic periodontitis and nifedipine-induced gingival overgrowth." | 3.78 | Clinical case report of long-term follow-up in type-2 diabetes patient with severe chronic periodontitis and nifedipine-induced gingival overgrowth. ( Fujinami, K; Shibukawa, Y; Yamashita, S, 2012) |
| "These results suggest that nifedipine can enhance insulin sensitivity and reduce white adipose tissue, possibly related to stimulation of adipocyte differentiation." | 3.77 | Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. ( Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Nakaoka, H; Senba, I; Sone, H, 2011) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 3.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| "The intraislet insulin hypothesis proposes that glucagon secretion during hypoglycemia is triggered by a decrease in intraislet insulin secretion." | 3.76 | ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. ( Bryan, J; Harmon, JS; Oseid, EA; Robertson, RP; Slucca, M, 2010) |
| "The combination with olmesartan and nifedipine, as well as a monotherapy with olmesartan, exerts preferable cardioprotection in diabetic mice exposed to recurrent hypoxia." | 3.76 | Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice. ( Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T, 2010) |
| " She would like to know whether she can continue using metformin during the pregnancy and also is concerned about the effect of the gastric bypass surgery." | 3.74 | A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery. ( Coustan, DR, 2008) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 3.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| " The effect of a 2-week treatment with nifedipine, captopril and prazosin upon glycaemia, serum insulin (IRI) and C-peptide (CP) following oral and intravenous glucose load were investigated in three groups, each including 10 non-diabetic patients with essential hypertension (h) and 10 hypertensive type 2 (non-insulin-dependent) diabetics (h + d), aged 32-63 years." | 3.69 | Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics. ( Czyzyk, A; Jasik, M; Kasperska-Dworak, A, 1996) |
| "A 66-year-old hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure was treated by adding enalapril, an angiotensin converting enzyme inhibitor, to the furosemide and nifedipine regimen because of an insufficient antihypertensive response for 1 month." | 3.69 | Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. ( Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K, 1994) |
| "The hypothesis that nifedipine may cause an insidious but reversible change in glucose tolerance, similar to that associated with thiazide therapy, was studied in six nondiabetic and six noninsulin-dependent diabetic patients with hypertension." | 3.67 | Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients. ( Al-Hussary, N; Atkins, TW; Beevers, DG; Gill, JS; Pasi, KJ; Zezulka, AV, 1987) |
| "The effects of nifedipine (Adalat) on glucose metabolism and insulin release were studied in rats and in patients with type 2 diabetes mellitus complicated with hypertension." | 3.67 | Effects of nifedipine on insulin secretion and glucose metabolism in rats and in hypertensive type 2 (non-insulin dependent) diabetics. ( Kajiyama, S; Kanatsuna, T; Kano, Y; Kitagawa, Y; Kondo, M; Mori, H; Nakamura, N; Nakano, K; Nishioka, H; Yoshida, T, 1985) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 2.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "Treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group, and especially in those with microalbuminuria." | 2.69 | Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. ( Chan, JC; Cheung, MY; Cheung, RC; Cockram, CS; Critchley, JA; Ko, GT; Leung, DH; Nicholls, MG; So, WY; Swaminathan, R, 2000) |
| "Treatment with nifedipine resulted in a rise in LDL-ox of 7-11% as compared to baseline (P<0." | 2.69 | Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study. ( Brosh, D; Levi, Z; Lidar, M; Rachmani, R; Ravid, M, 2000) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | 2.68 | Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment. ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| " However, lacidipine exhibited a lower incidence of adverse events (particularly ankle edema and tachycardia) than nifedipine SR." | 2.67 | Calcium antagonist antihypertensive treatment of non-insulin-dependent diabetics: efficacy and safety of lacidipine versus nifedipine SR. ( Circo, A; D'Onofrio, V; Gulizia, M; Platania, F; Rizzini, P; Valenti, R, 1994) |
| "Twenty-five stage 2 diabetic nephropathy patients, 39 stage 3 diabetic nephropathy patients, and 12 nondiabetic subjects performed five submaximal cycloergometric exercises (90% of theoretical heart rate) on nonconsecutive days." | 2.67 | Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. ( Bossoni, S; Caldonazzo, A; Cimino, A; Cravarezza, P; Giustina, A; Giustina, G; Romanelli, G, 1990) |
| " Neither acute nor chronic administration of nifedipine or placebo modified the glucose tolerance." | 2.66 | [Effects of nifedipine on carbohydrate metabolism in the non-insulin dependent diabetic]. ( Abadie, E; Fiet, J; Gauville, C; Passa, P; Tabuteau, F; Villette, JM, 1985) |
| "The pathogenesis of vascular calcification is incompletely understood, and until now, there have been no effective therapeutics for vascular calcification." | 1.91 | L-type calcium ion channel-mediated activation of autophagy in vascular smooth muscle cells via thonningianin A (TA) alleviates vascular calcification in type 2 diabetes mellitus. ( Li, P; Liu, R; Liu, Y; Shen, J; Sun, X; Wai Wong, VK; Wang, Q; Zhang, C; Zhao, M, 2023) |
| "Gingival overgrowth is a common side effect of calcium channel blockers used in the treatment of cardiovascular diseases." | 1.62 | Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. ( Miyashita, Y; Morikawa, S; Nakagawa, T; Nasu, M, 2021) |
| "Bladder function of db/db (type 2 diabetes) and wild type (Wt) mice was evaluated by behavioral tests and in vivo cystometry." | 1.40 | T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction. ( Chitaley, K; Jiang, X; Luttrell, I; Yang, CC, 2014) |
| "Nifedipine treatment decreased serum insulin level to one fifth of that in KK-A(y) mice without nifedipine." | 1.35 | Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2008) |
| "In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment." | 1.34 | Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. ( Inami, N; Iwasaka, T; Kimura, Y; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A, 2007) |
| "Does nifedipine treatment alone decrease the progression of renal disease with overt proteinuria? If these answers are yes, are these beneficial effects of nifedipine superior to that of other DHPs with equihypotensive properties? Does nifedipine treatment also reduce oxidative stress markers? Are these unique effects of nifedipine correlated with its anti-oxidative properties? These prospective studies will provide further valuable information whether nifedipine may be a preferred DHP to achieve BP goals in hypertensive patients with systolic dysfunction or overt proteinuria." | 1.34 | Revival of nifedipine, a dihydropyridine-based calcium blocker. ( Nakamura, K; Yamagishi, S, 2007) |
| " Nifedipine, a dihydropyridine-type calcium antagonist, improves endothelial function in hypercholesterolemia by enhancing nitric oxide function, and increases endothelial nitric oxide bioavailability by antioxidative mechanisms." | 1.33 | Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. ( Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A, 2005) |
| "Type 2 diabetes is increasing in prevalence and is predominantly managed in general practice." | 1.30 | A cautionary tale. ( Phillips, PJ; Popplewell, PY; Tallis, GA, 1997) |
| "Two groups of 5 patients with NIDDM (fasting blood glucose 139." | 1.28 | Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics. ( Charbonnel, B; Garnier, JM; Krempf, M; Ranganatan, S; Ritz, P, 1991) |
| "Nicardipine was used to control hypertensive episodes." | 1.27 | Blood glucose control by an artificial endocrine pancreas in a patient with phaeochromocytoma. ( Hamaji, M; Kawamori, R; Kawashima, Y; Mashimo, T; Miyata, M; Nakao, K; Shichiri, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (15.85) | 18.7374 |
| 1990's | 32 (39.02) | 18.2507 |
| 2000's | 21 (25.61) | 29.6817 |
| 2010's | 13 (15.85) | 24.3611 |
| 2020's | 3 (3.66) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Yang, H | 1 |
| Kuang, SJ | 1 |
| Zhang, L | 1 |
| Zhou, MY | 1 |
| Zeng, P | 1 |
| Zhang, MZ | 1 |
| Rao, F | 1 |
| Zhou, ZL | 1 |
| Deng, CY | 1 |
| Shen, J | 1 |
| Zhang, C | 2 |
| Liu, Y | 1 |
| Zhao, M | 1 |
| Wang, Q | 1 |
| Li, P | 1 |
| Liu, R | 1 |
| Wai Wong, VK | 1 |
| Sun, X | 1 |
| Morikawa, S | 1 |
| Nasu, M | 1 |
| Miyashita, Y | 1 |
| Nakagawa, T | 1 |
| Jiang, X | 1 |
| Luttrell, I | 1 |
| Chitaley, K | 1 |
| Yang, CC | 1 |
| Derosa, G | 4 |
| Querci, F | 2 |
| Franzetti, I | 2 |
| Dario Ragonesi, P | 1 |
| D'Angelo, A | 3 |
| Maffioli, P | 3 |
| Zhou, Y | 1 |
| Sun, P | 1 |
| Wang, T | 1 |
| Chen, K | 1 |
| Zhu, W | 1 |
| Wang, H | 1 |
| Mugellini, A | 2 |
| Pesce, RM | 2 |
| Cicero, AF | 2 |
| Tocci, G | 1 |
| Li, X | 1 |
| Luan, Q | 1 |
| Wang, X | 1 |
| Sha, Y | 1 |
| He, L | 1 |
| Cao, C | 1 |
| Jin, L | 1 |
| Slucca, M | 1 |
| Harmon, JS | 1 |
| Oseid, EA | 1 |
| Bryan, J | 1 |
| Robertson, RP | 1 |
| Yamashita, C | 1 |
| Hayashi, T | 2 |
| Mori, T | 1 |
| Matsumoto, C | 1 |
| Kitada, K | 1 |
| Miyamura, M | 1 |
| Sohmiya, K | 1 |
| Ukimura, A | 1 |
| Okada, Y | 1 |
| Yoshioka, T | 1 |
| Kitaura, Y | 1 |
| Matsumura, Y | 1 |
| Kim, Y | 1 |
| Park, K | 1 |
| Kang, W | 1 |
| Iwai, M | 2 |
| Kanno, H | 1 |
| Inaba, S | 1 |
| Senba, I | 1 |
| Sone, H | 2 |
| Nakaoka, H | 1 |
| Horiuchi, M | 2 |
| Yamamoto, E | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Shibukawa, Y | 1 |
| Fujinami, K | 1 |
| Yamashita, S | 1 |
| Ko, GT | 4 |
| Chan, HC | 2 |
| Lopatin, IuM | 1 |
| Kirakozov, DA | 1 |
| Statsenko, ME | 1 |
| So, WY | 2 |
| Tong, PC | 1 |
| Leung, WY | 1 |
| Chow, CC | 1 |
| Yeung, VT | 2 |
| Chan, WB | 1 |
| Critchley, JA | 2 |
| Cockram, CS | 5 |
| Chan, JC | 5 |
| Okoro, EO | 1 |
| Oyejola, BA | 1 |
| Bertone, G | 1 |
| Piccinni, MN | 1 |
| Fogari, E | 1 |
| Ciccarelli, L | 1 |
| Fogari, R | 1 |
| Moriyama, T | 1 |
| Oka, K | 1 |
| Ueda, H | 1 |
| Imai, E | 1 |
| Jerums, G | 1 |
| Allen, TJ | 1 |
| Campbell, DJ | 1 |
| Cooper, ME | 1 |
| Gilbert, RE | 1 |
| Hammond, JJ | 1 |
| O'Brien, RC | 1 |
| Raffaele, J | 1 |
| Tsalamandris, C | 1 |
| Nomura, S | 2 |
| Shouzu, A | 2 |
| Omoto, S | 2 |
| Nishikawa, M | 2 |
| Iwasaka, T | 2 |
| Yamagishi, S | 1 |
| Nakamura, K | 1 |
| Inami, N | 1 |
| Kimura, Y | 1 |
| Tsukuda, K | 1 |
| Mogi, M | 1 |
| Li, JM | 1 |
| Iwanami, J | 1 |
| Min, LJ | 1 |
| Sakata, A | 1 |
| Fujita, T | 1 |
| Yoshino, G | 2 |
| Iskenderov, BG | 1 |
| Burmistrova, LF | 1 |
| Berenshteĭn, NV | 1 |
| Lokhina, TV | 1 |
| Dohmen, W | 1 |
| Coustan, DR | 1 |
| García Puig, J | 1 |
| Mateos Antón, F | 1 |
| Gil Aguado, A | 1 |
| Barcina Sánchez, C | 1 |
| Nicholls, MG | 4 |
| Cheung, CK | 2 |
| Law, LK | 1 |
| Swaminathan, R | 3 |
| Gulizia, M | 1 |
| Valenti, R | 1 |
| Platania, F | 1 |
| D'Onofrio, V | 1 |
| Rizzini, P | 1 |
| Circo, A | 1 |
| Giordano, M | 3 |
| Matsuda, M | 1 |
| Sanders, L | 1 |
| Canessa, ML | 3 |
| DeFronzo, RA | 3 |
| Leung, DH | 2 |
| Tomlinson, B | 1 |
| Uchida, K | 1 |
| Azukizawa, S | 1 |
| Nakano, S | 1 |
| Kaneko, M | 1 |
| Kigoshi, T | 1 |
| Morimoto, S | 1 |
| Matsui, A | 1 |
| Ravid, M | 2 |
| Savin, H | 1 |
| Jutrin, I | 1 |
| Bental, T | 1 |
| Katz, B | 1 |
| Lishner, M | 1 |
| Gomis, R | 1 |
| Vidal, J | 1 |
| Novials, A | 1 |
| Coves, MJ | 1 |
| Okuda, Y | 1 |
| Mizutani, M | 1 |
| Kawakami, Y | 1 |
| Bannai, C | 1 |
| Yamashita, K | 2 |
| Crepaldi, G | 1 |
| Carraro, A | 1 |
| Brocco, E | 1 |
| Adezati, L | 2 |
| Andreani, D | 1 |
| Bompiani, G | 1 |
| Brunetti, P | 1 |
| Fedele, D | 1 |
| Giorgino, R | 1 |
| Giustina, G | 4 |
| Abbott, K | 1 |
| Smith, A | 1 |
| Bakris, GL | 2 |
| Agardh, CD | 1 |
| Garcia-Puig, J | 1 |
| Charbonnel, B | 2 |
| Angelkort, B | 1 |
| Barnett, AH | 1 |
| Sanders, LR | 1 |
| Castellino, P | 2 |
| Jasik, M | 1 |
| Kasperska-Dworak, A | 1 |
| Czyzyk, A | 1 |
| Yokoyama, H | 1 |
| Tomonaga, O | 1 |
| Hirayama, M | 1 |
| Ishii, A | 1 |
| Takeda, M | 1 |
| Babazono, T | 1 |
| Ujihara, U | 1 |
| Takahashi, C | 1 |
| Omori, Y | 1 |
| Kazumi, T | 1 |
| Hozumi, T | 1 |
| Ishida, Y | 1 |
| Tallis, GA | 1 |
| Phillips, PJ | 1 |
| Popplewell, PY | 1 |
| Solini, A | 1 |
| Takeda, S | 1 |
| Ueshiba, H | 1 |
| Hattori, Y | 1 |
| Irie, M | 1 |
| Cheung, RC | 1 |
| Cheung, MY | 1 |
| Rachmani, R | 1 |
| Lidar, M | 1 |
| Brosh, D | 1 |
| Levi, Z | 1 |
| Chan, CH | 1 |
| Baba, S | 1 |
| Minami, K | 1 |
| Yokokura, M | 1 |
| Ishizuka, N | 1 |
| Seino, S | 1 |
| Albergati, F | 1 |
| Paternó, E | 1 |
| Venuti, RP | 1 |
| Boeri, D | 1 |
| Lombardo, I | 1 |
| Semino, S | 1 |
| Viviani, GL | 1 |
| Romero, R | 1 |
| Salinas, I | 1 |
| Lucas, A | 1 |
| Teixidó, J | 1 |
| Audi, L | 1 |
| Sanmarti, A | 1 |
| Kawai, K | 1 |
| Suzuki, S | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
| Goto, T | 1 |
| Tateishi, T | 1 |
| Yoshimine, N | 1 |
| Kuzuya, F | 1 |
| Krempf, M | 1 |
| Ranganatan, S | 1 |
| Ritz, P | 1 |
| Garnier, JM | 1 |
| Andronico, G | 2 |
| Angileri, G | 1 |
| Piazza, G | 1 |
| Cerasola, G | 2 |
| Romanelli, G | 3 |
| Giustina, A | 3 |
| Cravarezza, P | 2 |
| Caldonazzo, A | 2 |
| Agabiti-Rosei, E | 2 |
| Monges, AM | 1 |
| Pisano, P | 1 |
| Aujoulat, P | 1 |
| Salducci, D | 1 |
| Durand, A | 1 |
| Panagides, D | 1 |
| Bory, M | 1 |
| Crevat, A | 1 |
| Janka, HU | 1 |
| Mehnert, H | 1 |
| Carone, MB | 1 |
| Mulè, G | 1 |
| Mangano, MT | 1 |
| Bossoni, S | 2 |
| Cimino, A | 1 |
| Demarie, BK | 1 |
| Chellingsworth, MC | 1 |
| Kendall, MJ | 1 |
| Wright, AD | 1 |
| Singh, BM | 1 |
| Pasi, J | 1 |
| Tentorio, A | 1 |
| Ghilardi, G | 1 |
| Pedroncelli, A | 1 |
| Benco, R | 1 |
| Stroppa, S | 1 |
| Adib, S | 1 |
| Gianola, D | 1 |
| Pagani, G | 1 |
| Girelli, A | 1 |
| Muiesan, ML | 1 |
| Muiesan, G | 1 |
| Heyman, SN | 1 |
| Heyman, A | 1 |
| Halperin, I | 1 |
| Gasparoni, P | 1 |
| Caroli, A | 1 |
| Berno, R | 1 |
| Cecchetto, G | 1 |
| Zanlungo, P | 1 |
| Sardeo, G | 1 |
| Carbone, G | 1 |
| Volpi, A | 1 |
| Raman, PG | 1 |
| Mishra, VN | 1 |
| Singh, D | 1 |
| Gill, JS | 1 |
| Al-Hussary, N | 1 |
| Zezulka, AV | 1 |
| Pasi, KJ | 1 |
| Atkins, TW | 1 |
| Beevers, DG | 1 |
| Collins, WC | 1 |
| Cullen, MJ | 1 |
| Feely, J | 1 |
| Connacher, AA | 1 |
| el Debani, AH | 1 |
| Isles, TE | 1 |
| Stevenson, IH | 1 |
| Madhu, S | 1 |
| Singh Verma, NP | 1 |
| Singh, B | 1 |
| Kanatsuna, T | 1 |
| Nakano, K | 1 |
| Mori, H | 1 |
| Kano, Y | 1 |
| Nishioka, H | 1 |
| Kajiyama, S | 1 |
| Kitagawa, Y | 1 |
| Yoshida, T | 1 |
| Kondo, M | 1 |
| Nakamura, N | 1 |
| Abadie, E | 1 |
| Villette, JM | 1 |
| Gauville, C | 1 |
| Tabuteau, F | 1 |
| Fiet, J | 1 |
| Passa, P | 1 |
| Hamaji, M | 1 |
| Miyata, M | 1 |
| Kawamori, R | 1 |
| Shichiri, M | 1 |
| Mashimo, T | 1 |
| Nakao, K | 1 |
| Kawashima, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nifedipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabet | 2006 |
41 trials available for nifedipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines | 2015 |
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2016 |
Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction. A 1-year clinical study comparing the effects of amlodipine and nifedipine retard on ambulatory blood pressure and left ventricular systol
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; C | 2003 |
Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols | 2003 |
Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubl
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Cholesterol; Chol | 2004 |
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mel | 2004 |
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation | 2007 |
[Investigation on the blood pressure-independent nephroprotective effect of nilvadipine in type 2 diabetics].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; | 2008 |
[Can the "double blind" be recognized before the identifying codes are revealed?].
Topics: Albuminuria; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hy | 1995 |
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P | 1995 |
Calcium antagonist antihypertensive treatment of non-insulin-dependent diabetics: efficacy and safety of lacidipine versus nifedipine SR.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cholesterol; Delay | 1994 |
The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM.
Topics: Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; China; Cholesterol | 1994 |
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Topics: Adult; Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 1993 |
Effects of isradipine and nifedipine retard in hypertensive patients with type II diabetes mellitus.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; | 1993 |
The effect of nilvadipine on bloodflow in the dorsal pedis artery in type 2 diabetic patients--a study using duplex Doppler ultrasonography.
Topics: Arteries; Blood Flow Velocity; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Foot; Hu | 1995 |
Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 1995 |
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
Topics: Adult; Albuminuria; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, S | 1996 |
Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine.
Topics: Adolescent; Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blin | 1996 |
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1996 |
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1997 |
Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Antiporters; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; D | 1997 |
Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus.
Topics: Aged; C-Peptide; Calcium Channel Blockers; Catecholamines; Chromatography, High Pressure Liquid; Cro | 1999 |
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diabetes Mellitus, Type 2; | 2000 |
Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cro | 2000 |
Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial.
Topics: Administration, Oral; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, | 2001 |
Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Disea | 2001 |
Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients.
Topics: Blood Glucose; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyc | 1992 |
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis.
Topics: Albuminuria; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Enalapril; | 1992 |
Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Blood Glucose; Blo | 1992 |
Metabolic effects of enalapril and nifedipine in diabetic hypertensives.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Enalapril; Glycated Hemoglobin; Humans; Hypertension; Insu | 1991 |
Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine.
Topics: Adolescent; Adult; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetes Melli | 1991 |
[Antihypertensive therapy with co-dergocrine mesilate/nifedipine in comparison with nifedipine in type II diabetes].
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dihydroergotoxine | 1990 |
Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy.
Topics: Administration, Oral; Adolescent; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Capt | 1990 |
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus.
Topics: Aged; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Di | 1990 |
The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Diltiazem; Female; Fruc | 1989 |
Short-term effect of captopril and nifedipine on micro-albuminuria induced by exercise in hypertensive diabetic patients.
Topics: Albuminuria; Captopril; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Evaluation; Exerc | 1989 |
Calcium channel blocker drugs and diabetic control.
Topics: Adult; Aged; Blood Glucose; Calcium Channel Blockers; Clinical Trials as Topic; Diabetes Mellitus, T | 1987 |
Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glipizide; Humans; | 1987 |
[Effects of nifedipine on carbohydrate metabolism in the non-insulin dependent diabetic].
Topics: Adult; Aged; Arginine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Bl | 1985 |
40 other studies available for nifedipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Contribution of calcium dysregulation to impaired coronary artery contraction in Zucker diabetic fatty rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Calcium; Calcium Channe | 2023 |
L-type calcium ion channel-mediated activation of autophagy in vascular smooth muscle cells via thonningianin A (TA) alleviates vascular calcification in type 2 diabetes mellitus.
Topics: Animals; Autophagy; Calcium; Calcium Channels, L-Type; Cells, Cultured; Core Binding Factor Alpha 1 | 2023 |
Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Gingival Overgrowth; Humans; | 2021 |
T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction.
Topics: Acetylcholine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type | 2014 |
Inhibition of Calcium Influx Reduces Dysfunction and Apoptosis in Lipotoxic Pancreatic β-Cells via Regulation of Endoplasmic Reticulum Stress.
Topics: Animals; Apoptosis; Calcium Signaling; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diazoxide; Endop | 2015 |
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
Nifedipine intake increases the risk for periodontal destruction in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Calcium Channel Blockers; Cohort Studies; Cros | 2008 |
ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation.
Topics: Animals; Calcium Channels; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mell | 2010 |
Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Hypoxia; Imidazoles; Ma | 2010 |
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cy | 2010 |
Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Topics: Adipocytes; Adipogenesis; Adiponectin; Adipose Tissue, White; Animals; Blood Glucose; Calcium Channe | 2011 |
Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dia | 2010 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
Clinical case report of long-term follow-up in type-2 diabetes patient with severe chronic periodontitis and nifedipine-induced gingival overgrowth.
Topics: Calcium Channel Blockers; Chronic Periodontitis; Diabetes Mellitus, Type 2; Gingival Overgrowth; Gly | 2012 |
[Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bl | 2003 |
Treating high blood pressure in Africans with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazines; Calcium Channe | 2004 |
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2004 |
Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Blood Pressure; Calcium Channel Blockers; Case-Control Studies; Chemokine CCL2; Ch | 2005 |
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Topics: Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diabet | 2007 |
Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Biomarkers; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, | 2007 |
Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine.
Topics: Animals; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Cognition; Cognition Disorder | 2008 |
A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery.
Topics: Adult; Antihypertensive Agents; Breast Feeding; Diabetes Mellitus, Type 2; Female; Gastric Bypass; G | 2008 |
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1995 |
Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Furos | 1994 |
Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.
Topics: Adult; Antihypertensive Agents; Blood Glucose; C-Peptide; Calcium Channel Blockers; Captopril; Diabe | 1996 |
Insulin responses to oral glucose during 4-year treatment with nifedipine retard in hypertensive patients with and without NIDDM.
Topics: Administration, Oral; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Glucose; Glucose Toleranc | 1997 |
A cautionary tale.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Calcium Channel Blockers; Ch | 1997 |
Normalization of intracellular Ca(2+) induces a glucose-responsive state in glucose-unresponsive beta-cells.
Topics: Calcium; Calcium Channel Blockers; Calcium Channels; Cell Line; Diabetes Mellitus, Type 2; Glucose; | 2002 |
Nocturnal blood pressure monitored by ambulatory blood pressure measurement in elderly hypertensive patients.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Cerebral Infarction; Circadian Rhythm; Diabetes | 1992 |
Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics.
Topics: Aged; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucose; Humans; I | 1991 |
1H nuclear magnetic resonance and clinical studies of interaction of calcium antagonists and hypoglycemic sulfonylureas.
Topics: Adenosine Triphosphate; Aged; Binding Sites; Blood Glucose; Calcimycin; Calcium; Chromatography, Gas | 1991 |
[Arterial hypertension caused by low renin: comparison of the calcium antagonist nifedipine and the ACE-inhibitor enalapril as to antihypertensive efficacy].
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Enalapril; Female; Humans; Hypertension; Male; Middle Age | 1990 |
Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hyperte | 1989 |
Diabetogenic effect of nifedipine.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypertension; Male; Middle Aged; Nifedipine | 1989 |
[Long-term treatment with nifedipine does not alter carbohydrate tolerance in normal subjects and does not worsen metabolic control in diabetics].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Huma | 1987 |
Nifedipine induced gingival hyperplasia.
Topics: Diabetes Mellitus, Type 2; Female; Gingival Hyperplasia; Humans; Middle Aged; Myocardial Infarction; | 1988 |
Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Fructosamine; Glucose Tolerance Test; Hexosamines; | 1987 |
Nifedipine in angina and blood glucose levels in diabetics.
Topics: Angina Pectoris; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Nifedi | 1986 |
Effects of nifedipine on insulin secretion and glucose metabolism in rats and in hypertensive type 2 (non-insulin dependent) diabetics.
Topics: Aged; Animals; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Glycated Hemoglob | 1985 |
Blood glucose control by an artificial endocrine pancreas in a patient with phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Blood Glucose; Calcium Channel Blockers; Catecholamines; Diabetes Mellitus, | 1985 |